FEB 1 3 2006

	103	<u> </u>			
AMENDMENT RANSMITTAL LETTER					Docket No. 0147-0250P
Application No. 10/617,835-Conf. #8238		Filing Date July 14, 2003		Examiner S. Kaushal	Art Unit 1633
Applicant(s): Tho					
NUCLE		ECULES ENC		TEINS WHICH IMP	ART THE ADHESION
AS Amendment Commissioner for P.O. Box 1450 Alexandria, VA 223 Transmitted here	313-1450	ndment in the	above-identif	ied application.	
The fee has been	n calculated an	d is transmitte	d as shown b	elow.	
		CLAIM	S AS AMEN	DED	
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	.9	- 20 =		Х	
Independent Claims	1	- 3 =		x	
Multiple Depend	dent Claims (ch	eck if applicabl	e)		
Other fee (please specify): Extension for response within second month					225.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					225.00
Large Entity				x Small Entity	
No additiona	al fee is require	d for this amer	ndment.		
	ge Deposit Acc			n the amount of $\$ _	·•
=	he amount of \$		is enclo	sed.	
Payment by	credit card. Fo	orm PTO-2038	is attached.		
	r is hereby auth d below. A dup			Deposit Account Nenclosed.	o. <u>02-2448</u>
x Credit a	ny overpaymer	nt.			
x Charge	any additional fili	ing or application	n processing	fees required under 3	37 CFR 1.16 and 1.17.
Gerald M. Murr Attorney Reg		>		Dated:	February 13, 2006
BIRCH, STEWA 8110 Gatehous Suite 100 East		H & BIRCH, LI	LP		
P.O. Box 747 Falls Church, V (703) 205-8000		0747			



Docket No.: 0147-0250P

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Thomas F. MEYER et al.

Application No.: 10/617,835

Confirmation No.: 8238

Filed: July 14, 2003

Art Unit: 1633

For: NUCLEIC ACID MOLECULES ENCODING

Examiner: S. Kaushal

PROTEINS WHICH IMPART THE ADHESION OF NEISSERIA CELLS TO HUMAN CELLS

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated September 13, 2006, please amend the aboveidentified U.S. patent application as follows:

Remarks/Arguments begin on page 2 of this paper.